Article de revue
Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030
Background: To date, global priorities for new vaccine R&D have not been systematically identified for endemic pathogens. As part of Immunisation Agenda 2030 (IA2030), we have systematically identified priority endemic pathogens for new vaccine R&D based on country and regional stakeholder values to address this need.
Methods: MCDA surveys targeting policy makers and immunisation stakeholders in each World Health Organization (WHO) region were used to weight eight criteria for prioritisation. Applying those weights to regional pathogen data yielded regional top ten pathogen lists, which are intended to inform regional deliberations on R&D priorities. The regional top ten lists were combined into an IA2030 global priority list. To inform R&D, use cases for new vaccines and monoclonal antibodies were identified, then categorized in terms of the activities needed to accelerate progress.
Findings: In five out of six WHO regions, Annual deaths in children under five and Contribution to antimicrobial resistance were the most heavily weighted criteria. How participants weighted the criteria was not associated with their region, biographical characteristics, or areas of expertise. Five pathogens were common priorities across all regions: M tuberculosis, HIV-1, K pneumoniae, S aureus, and Extra-intestinal pathogenic E coli. Six pathogens were priorities in single regions. Combining regional top ten lists provided a global list of 17 priority pathogens for new vaccine R&D. Thirty-four distinct use cases were identified for new products targeting these pathogens. While most are in the "Advance product development" category, ten are in the "Research" category and seven are in the "Prepare to implement" category.
Interpretation: These priorities for new vaccine R&D will help stakeholders better respond to regional and country needs. The use cases will inform R&D and enable monitoring of R&D under IA2030.
Auteurs
-
Mateusz Hasso-Agopsowicz
Voir le profil | Plus d’articles -
Angela Hwang
Voir le profil | Plus d’articles - Maria-Graciela Hollm Delgado
- Isis Umbelino-Walker
- Ruth A. Karron
- Raman Rao
-
Kwaku Poku Asante
Voir le profil | Plus d’articles -
Meru Sheel
Voir le profil | Plus d’articles -
Erin Grace Sparrow
Voir le profil | Plus d’articles -
Birgitte K. Giersing
Voir le profil | Plus d’articles
Langues
- Anglais
Année de publication
2024
Journal
EBioMedicine
Volume
110
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Organisations
- Organisation Mondiale de la Santé (OMS)
Mots-clés
- Recherche et développement (R&D)
RD-PRIORITIES
Cette ressource apparaît sur le Thème suivant:
Cette ressource est incluse dans le tableau suivant:
| Titre | Auteur | Année | Type | Langue |
|---|---|---|---|---|
| Partnering with regions and countries to identify priority pathogens for vaccines, October 2022 | Vaccine Prioritization & Platforms Team | 2022 | Presentation | Anglais |
| Partnering with regions and countries to identify priority pathogens for vaccines, December 2023 | Vaccine Prioritization & Platforms Team | 2023 | Presentation | Anglais |
| Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030 | Mateusz Hasso-Agopsowicz, Angela Hwang, Maria-Graciela Hollm Delgado, Isis Umbelino-Walker, Ruth A. Karron, Raman Rao, Kwaku Poku Asante, Meru Sheel, Erin Grace Sparrow, Birgitte K. Giersing | 2024 | Journal article | Anglais |